Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs

References

• Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), Bethesda, MD: National Cancer Institute, 2012. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/ [Last accessed 9 July 2012]
   Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer Statistics, 2014. CA Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40
   PubMed Web of Science ®Google Scholar
• Gleevec [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2012
   Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-63
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3 year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123:494-500
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26:2197-203
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomized ENESTnd trial. Lancet Oncol 2011;12:841-51
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123-9
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med 2010;362:2251-9
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Inc. NCCN Guidelines Version 1.2015 chronic myelogenous leukemia. 2014. Available at: https://doi.org/http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf
   Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381-8
   PubMed Web of Science ®Google Scholar
• Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hemotol 2011;86:471-4
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: justum pretium – the just price. J Clin Oncol 2013;31:3600-4
   PubMed Web of Science ®Google Scholar
• Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010;26:61-9
   PubMed Web of Science ®Google Scholar
• Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care 2003;41:761-4
   PubMed Web of Science ®Google Scholar
• Sales AE, Liu CF, Sloan KL, et al. Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population. Med Care 2003;41:753-60
   PubMed Web of Science ®Google Scholar
• Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003;41:84-99
   PubMed Web of Science ®Google Scholar
• Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expenditures. Am J Manag Care 2006;12:110-19
   PubMed Web of Science ®Google Scholar
• Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25:481-96
   PubMed Web of Science ®Google Scholar
• Wu EQ, Guerin A, Yu AP, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010;26:2861-9
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia. London (UK): National Institute for Health and Clinical Excellence (NICE), 2012 Apr. 74 p. (Technology appraisal guidance; no. 251). Available at: http://guideline.gov/content.aspx?f=rss&id=36883 [Last accessed 26 March 2014]
   Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35
   PubMed Web of Science ®Google Scholar
• Yhim HY, Lee NR, Song EK, et al. Imatinib mesylate discontinuation in patients with chronic myeloid leukaemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 2012;36:689-93
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease results from the TWISTER study. Blood 2013;122:515-22
   PubMed Web of Science ®Google Scholar
• Thielen N, van der Holt B, Cornelissen JJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomized trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer 2013;49:3242-6
   PubMed Web of Science ®Google Scholar
• Bosulif [prescribing information]. New York, NY: Pfizer Inc., 2012
   Google Scholar
• Iclusig [prescribing information]. Cambridge, MA: Ariad Pharmaceuticals Inc., 2012
   Google Scholar